- Book Chapter
- 10.1007/978-3-658-37849-3_1
A Professor in Ghana: Norbert Elias, civilising processes and the African challenge. An introduction by the editors
- Jan 01, 2022
- Dieter Reicher + 3 more +3
Publications from 2021 to 2026
Showing 10 of 13 papers
A Professor in Ghana: Norbert Elias, civilising processes and the African challenge. An introduction by the editors
COVID-19 vaccines a global public good? Moving past the rhetoric and making work of sharing intellectual property rights, know-how and technology.
Country differences in hospitalisation, length of stay, admission to Intensive Care Units, and mortality due to SARS-CoV-2 infection at the end of the first wave in Europe: a rapid review of available literature
Abstract ObjectivesCoronavirus disease (COVID-19) caused by the SARS-CoV-2 virus is spreading rapidly worldwide and threatening the collapse of national health care systems. The development of effective resource models are critical for long term health planning. The aim was to evaluate the available literature, to consider parameters affecting hospital resources, to effectively guide health policy and planning for future waves of infection.DesignA detailed search of the literature, using Google Scholar, PubMED, MedRxiv and BioRxiv, was conducted for the time period 1stDec 2019 to 31stMay 2020; using appropriate keywords: resultant articles were scrutinised in detail, and appraised for reported data pertaining to hospitalization and hospital length of stay (LOS).ResultsDisease presentation was described in China; 81 % mild, 14 % moderate and 5 % severe. The experience, thus far, in Europe and the USA are suggestive of a higher degree of severity. Initial reports suggest high hospitalisation and ICU admittance rates. More recent reports from the European Centre for Disease Prevention and Control (ECDC) lower this estimation. Perhaps the relative age, the level of pre-existing conditions, and other health factors may be contributors to differences. Data from Irish cases suggest hospitalisation rate may be lower in parts of Europe and time dependent. Hospital LOS is described in 55 articles, with median lengths of stay between 3 and 52 days. The evidence regarding the LOS in ICU is reported in 31 studies, 26 deemed relevant. The majority of studies report ICU LOS between 7 to 11 days. Many of these studies are likely skewed towards shorter stay due to study cut-off dates. Indications based on ICU LOS reported for patients continuing care suggest median ICU stay will progressively increase.ConclusionsThese parameter estimates are key to the development of an effective health care resource model. Based on our appraisal of the literature, is it essential that Europe manages mitigation measures to ensure that hospital and ICU capacity does not become overwhelmed to manage COVID-19 in subsequent infection waves.Strengths and limitations of this studyThe study provides timely information on the differences in hospitalisation, length of stay and ICU length of stay due to COVID-19 in a number of countries worldwide at the end of wave one in Europe;This rapid review builds on a previously available review paper that reported length of stay in the early phase of the pandemic; many more studies outlining length of stay, and in particular, ICU length of stay, are now available;This rapid review reports on study mortality rate giving an interesting insight into differences across countries and continents;Limitations associated with any rapid review are pertinent to this study; a narrow aim was set, and the sources of the literature may be limited by the time-limited constraint of gathering relevant literature; and a number of articles available were in pre-print form and only undergoing peer review; andThis rapid review provides evidence-based estimates of Hospital and ICU length of stay due to COVID-19 infection across a number of countries to steer policy and provide parameter estimates for utilisation within a hospital resource model as preparations are made for subsequent waves of infection.
Read moreSAT0733-HPR Dutch recommendations for physical therapy in axial spondyloartrhritis (AXSPA)
BackgroundAccording to the ASAS/EULAR recommendations, physical therapy (PT), especially exercise therapy, is an essential element within the management of axSpA.1 In the Netherlands considerable variation in the delivery of PT was observed,2 suggesting suboptimal care delivery. This practice variation is likely to be related to the lack of specific recommendations regarding referral, assessment, content, and monitoring of its effectiveness and safety.ObjectivesTo develop practice recommendations on PT in axSpA.MethodsA taskforce of 31 experts was responsible for the recommendations. It consisted of patients(,2 rheumatologists(,7 physical therapists(,13 policy makers(,3 researchers(2 and representatives of patient organisations(.4 These were based on scientific evidence, expert opinion and patient values and were formulated following a combination of literature review and three expert-group meetings. Clinical questions were formulated in the first expert-group meeting. Then, a systematic literature review was performed to answer the clinical questions. It focused on systematic reviews, meta-analyses and (inter)national guidelines recommendations and consensus statements published after 2010 in English or Dutch. When this approach did not yield sufficient information, relevant RCTs or other types of research designs addressing (one of) the clinical questions were selected. Subsequently, draft recommendations based on the literature, expert opinion and patient values were formulated and discussed in a second meeting. In the third expert group meeting the recommendations were finalised and the level of agreement was determined by a written voting (rating from 1 (total disagreement) to 10 (total agreement)). We defined agreement if at least 80% voted ≥8.ResultsIn the first meeting 18 clinical questions were formulated. Six questions pertaining to the content and safety of PT were merged and integrated. In total 12 practice recommendations were formulated on indication(,2 referral(,2 assessment/monitoring(,2 treatment(,5 reporting(1 and safety(.2 (Figure 1) Three recommendations were (partly) based on level 1 evidence (Dutch Evidence Based guidelines, EBRO); others were based on lower levels combined with the opinion of experts written in literature. Agreement was reached for 11 out of 12 recommendations. Mean levels of agreement were high and varied between 8,5–9,1. SAT0733HPR – Figure 1Short description of the content of the Dutch recommendations for physical therapy in axial Spondyloartrhritis (axSpA)ConclusionsUsing a standardised process of professional guideline development, 12 practice recommendations for PT management of patients with axSpA were developed. They can guide clinicians and physiotherapists dealing with patients wiht axSpA, ultimately leading to a delivery of a better care. Next steps are the ratification by relevant professional societies as well as dissemination and implementation.
Read morePARE0015 Large-scale survey offers general insight and basis for policy drafting
BackgroundThe Dutch Arthritis Foundation (DAF) commissioned a large-scale survey to gain a broad insight into the various aspects of living with RMDs in the Netherlands. The results offer an insight into the prevalence of RMDs, as well as into living with RMDs and the use and standard of relevant healthcare and social care in our country. This was the first survey of this scale in the Netherlands.ObjectivesThe survey aimed to generate data about the prevalence and the impact of RMDs on people’s every-day lives in the Netherlands. The DAF will use the results to better inform parties involved in caring for people with RMDs and to help them with policy drafting, such as authorities, healthcare insurers and healthcare providers.MethodsThe bulk of all data consists of statistical data from the NIVEL Healthcare Registrations (from 355 GP clinics, which register 1.1 million RMD patients). The survey also built on statistical and qualitative data from Vektis (business intelligence centre for the healthcare industry) and the National Institute of Public Health and Environmental Protection. Patients were contacted through the National Panel for Chronical Patients and asked to score their quality of life, the impact RMD has on their lives, and the standard of care. Rheumatologists, health professionals in rheumatology and orthopaedics were also represented in the monitoring group. The survey was carried out for four key disorders – chronic inflammatory rheumatism, osteoarthritis, gout and osteoporosis. These disorders are registered by both GPs and specialists. Fibromyalgia is not registered as a specific disorder by GPs and was therefore outside the scope of the survey.Results:The report generated the following results for the more than two million people with RMDs in the Netherlands:1 in 9 people have a RMD; More than 2 million people have a RMD; Every day, 700 people are diagnosed with a form of RMD; There are 1.3 million people with osteoarthritis; 400,000 people with osteoporosis; 370,000 people with gout; 220,000 people with inflammatory rheumatism such as RA, ax-SpA, SLE, Sjögren syndrome and scleroderma.69% of people with RMD are restricted by their symptoms in their day to day life;50% of people with RMD between the ages of 40 and 65 are not in paid employment;54% of people with RMD indicate they suffer from loneliness;50% of people with RMD deal with incomprehension;65% uses medication, 37% physiotherapy.ConclusionsThe report shows the extent of the impact of RMDs, not only medically, but also with regard to social effects. This was the first study to adequately reveal the sense of loneliness among RMD patients, laying bare the incomprehension they face in others. It also studied the impact of RMDs on employment, the great reliance on voluntary carers, and the fact that many people with a RMD also suffer other symptoms. The report was able to pinpoint the most vulnerable patients, and therefore provides a clear indication as to where improvements can be made. It also clearly shows that there is room for improvement when it comes to the registration of specific disorders such as fibromyalgia, but also disorders classed as a form of inflammatory arthritis, to enable the generation of objective data from the registration systems.Disclosure of InterestNone declared
Read moreEvaluating quality of care in rheumatoid arthritis: the patient perspective
As rheumatoid arthritis (RA) is a potentially disabling disease, affecting up to 1% of the population, structural monitoring of standardised outcomes to identify best healthcare practices is vital to quality improvement.1 2 Seven sets of RA standardised outcomes or ‘quality indicators’ have been described in the literature.3 However, only one group involved patients.4 This lack of patient representation in the current indicator sets might be due to the common methodology of indicator selection: indicators are determined through systematic searches of evidence-based literature and consultation of experts, usually defined as clinicians or researchers, rather than patients. Studies have shown that patients and healthcare providers have different perspectives regarding quality of care.5 6 As the patient is the customer in the business called ‘health care’, the quality of the product should meet the costumers’ needs. Therefore, we have studied the patient’s perspective on quality of care in order to incorporate this together with the clinician’s perspective into quality indicators. Patients were consulted using focus group methodology in combination with an online survey. The focus group method is a well-established research technique, gathering rich, descriptive data from participants in a small and homogeneous group, who focus on a specific topic, while guided by a neutral moderator.7 ### Study sample and procedure #### Phase I: focus group discussion Nine patients of the established patient partner network of the Dutch Arthritis Foundation were invited to the focus group discussion (FGD). Participants received an invitation and written information on the topic of the study by email. Prior to the meeting all patients gave oral consent to record the meeting and to use the results of this meeting for research purposes. Transcripts of the recording were analysed by one researcher (SM). The moderator (MvO) explained the purpose of the discussion, created a ‘safe environment’ and ensured that participants did not deviate too much from the topic. …
Read moreAnalgesic use by Dutch osteoarthritis patients
PARE0014 Patient Advocacy for Better Information on Biosimilars and Switching
OP0253-PARE “Samen Reuma”- A Closed Group on Facebook for People with Rheumatic Diseases
PARE0021 National Arthritis Activity Guide (Reumabeweegwijzer) Directs Patients to Physical Activities in their Own Neighborhood